The bank estimates that weight-loss drugs, called GLP-1 agonists, could increase the nation's GDP by an extra 1% over the next decade, the equivalent of about $360 billion per year.
Independent pharmacists are dealing with the same financial pressures as the larger companies and lack control over revenue from their main product, prescription drugs.